Parallax Volatility Advisers
ANIK icon

Parallax Volatility Advisers’s Anika Therapeutics ANIK Stock Holding History

Parallax Volatility Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-70,000
Closed -$2.12M – 2516
2019
Q1 		$2.12M Buy
+70,000
New +$2.4M ﹤0.01% 980

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parallax Volatility Advisers's ANIK Position: Q1 2020 in Review

Parallax Volatility Advisers sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 23,351 shares — an estimated $1.21M sold.

Parallax Volatility Advisers first reported a position in ANIK in Q4 2017 and held it in 7 quarters. The position peaked at $1.47M in Q2 2019. 164 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Parallax Volatility Advisers reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 23,351 Anika Therapeutics shares in Q1 2020, an estimated $1.21M.
  • Parallax Volatility Advisers first reported a position in Anika Therapeutics in Q4 2017 and held it in 7 quarters.
  • Parallax Volatility Advisers's Anika Therapeutics position peaked at $1.47M in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Parallax Volatility Advisers's 13F filing for Q1 2020, filed 15 May 2020.